OICR offers a number of funding opportunities for Ontario researchers throughout the year to help enable world-class cancer research across the province.
Current Funding Opportunities
The Cancer Therapeutics Innovation Pipeline (CTIP) Program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery to create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) to attract partnerships and/or investment for further preclinical and clinical development. To generate a sustainable pipeline, CTIP will support projects that aim to provide increasing evidence of target validation and disease association using functional assays and drug screening in relevant in vitro and in vivo models of the cancer type of interest.
CTIP funds projects in three stages of preclinical drug discovery and is currently inviting applications for the following two funding streams:
Early Accelerator projects: Delivers a validated primary assay to enable initial screening of molecules against a defined target. Entry into the EA stage requires evidence of target validation and association to the cancer of interest.
Funding available: Up to $150,000 for up to one year.
Late Accelerator projects: Delivers confirmed Hit molecules against a defined target, supported by evidence of disease association, using validated primary, secondary and orthogonal assays for screening. To achieve this goal, the project must describe an integrated testing cascade of experiments focused on achieving target validation in cell-based models coupled with medium-to-high-throughput screening for Hits.
Funding available: Up to $250,000 per year for up to two years.
OICR invites applications from investigators at Ontario academic centres, hospital research institutes, or other government research institutions. CTIP funding is only tenable in Ontario and can only be disbursed to not-for-profit entities.
- Notice of Intent submission: No later than July 7, 2021 by 5 p.m. ET
- Letter of Intent deadline: July 7, 2021 by 5 p.m. ET
- Full application deadline: September 15 by 5 p.m. ET
- Notification of results: By December 2021
- Funding start date: December 1, 2021
To accelerate translational cancer research so that precise, impactful and cost-effective treatments can benefit cancer patients, OICR has implemented a new Clinical Translation Pathway (CTP). The CTP will support practice-changing research in biomarkers, diagnostics and therapeutics that will advance early detection and intervention research and have a clear path to the clinic and clinical impact. It will focus on primary-diagnosed or early recurrent cancers. The pathway will be fueled by innovations emerging from OICR-supported research and from research originating from across the province of Ontario.
The CTP consists of separate funding streams that support preclinical, clinical, and convergent research. OICR is currently inviting applications for the following two funding streams:
Pre-Clinical Acceleration Team Awards (Pre-CATA): Supports pre-clinical projects with a clear path to the clinic, with a focus on pre-clinical development of biomarkers, diagnostics and therapeutics.
Funding available: $250,000 per year for up to three years. OICR anticipates supporting up to eight Pre-CATA projects.
Clinical Acceleration Team Awards (CATA): Supports early phase (I-II), prospective, biomarker-rich trials for clinical validation of biomarkers, diagnostics and therapeutics.
Funding available: $500,000 per year for up to three years. OICR anticipates supporting up to eight CATA trials.
- Notice of Intent submission: No later than May 10, 2021
- Letter of Intent deadline: May 10, 2021 by 5 p.m. EDT
- Full application deadline: August 12, 2021 by 5 p.m. EDT
- Notification of results: End of September 2021
- Funding start date: October 1, 2021
Subscribe for New Opportunities
Only active opportunities are listed here. To be notified of new opportunities, please subscribe to our mailing list.